Concept, Approach & Mission

Breadcrumb other pages

ERINHA’s concept

ERINHA-ASIBL (European Research Infrastructure on Highly Pathogenic Agents) is a pan-European Research Infrastructure dedicated to the study of High-consequence pathogens of Risk Group 4 (RG4). As a distributed Research infrastructure, it brings together leading European Bio-Safety Level 4 (BSL4) facilities and national research institutes with longstanding experience of research in this field. Such a coordinated approach is vital in a context marked by frequent globalization of infectious diseases with high risk for public health, society and economy.
The over-arching goal of ERINHA’s Infrastructure research concept is to provide capacities to conduct projects which are broad in scope, ambition and require a range of capabilities inside and outside BSL4 facility that no single facility can provide on its own.
The access to the ERINHA is organized through its Central Coordinating Unit, hosted in Paris.

Since 2019 ERINHA is operational and provides access to its full range of services including the state-of- art high containment facilities.


The globalization of infectious diseases and recent epidemics of Ebola, Zika, demonstrate the reality of dangerous infectious threats and the worldwide vulnerability towards them. Coordinated and prompt access to a large variety of high containment and complementary research capacities with high quality services enabling the excellence-driven research is required to be able to prevent and respond to the epidemics.
High containment facilities are rare and costly resources. Currently ERINHA is the only Research Infrastructure of its kind in Europe and worldwide and therefore represents a fundamental added value contributing to the European excellence in the field of research, competitiveness, innovation and preparedness.


Research carried out in the ERINHA infrastructure is intended to contribute to the overarching mission of protecting human health by increasing Europe’s preparedness for and capability to respond to an existing high consequence infectious disease or a newly emerged infectious disease threat.